Berlin, Germany, and Durham, N.C., USA, April 20, 2026\u00a0\u2013\u00a0AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it has introduced its proprietary, commercially ready manufacturing process to supply ametefgene parvec (AB-1005), an investigational gene therapy for the treatment of Parkinson\u2019s disease (PD) and multiple system atrophy-parkinsonian type (MSA-P), following submission of a United States Food and Drug Administration (FDA) Investigational New Drug Application (IND) amendment.<\/p>\n
This enables AskBio to now advance its REGENERATE-PD Phase II clinical trial in the United States with the material produced at the commercial manufacturing facility of AskBio\u2019s wholly owned subsidiary, Viralgen, with other trial sites to follow, using an intensified, high-efficiency, next-generation large-scale suspension manufacturing process that provides a consistently high purity product.<\/p>\n
\u201cToday\u2019s news marks another important advancement in our Parkinson\u2019s program,\u201d said Canwen Jiang, MD, PhD, Chief Development Officer and Chief Medical Officer at AskBio. \u201cWe are initiating supply with our manufacturing platform, to deliver our investigational gene therapy to participants in our ametefgene parvec trials, including our REGENERATE-PD trial, which recently saw the randomization of our first participants in Germany. The trial is currently enrolling participants in Poland, the United Kingdom, and the United States.\u201d<\/p>\n
\u201cManufacturing efficiency of our AAV gene therapy-based drug product is mission critical for our Phase II Parkinson\u2019s disease trial,\u201d said Christian Rommel, PhD, Global Head of Research and Development for Bayer\u2019s Pharmaceuticals Division. \u201cIt underscores the innovation of our production technology and reflects our continued commitment to meet high regulatory standards.\u201d<\/p>\n
In December 2025, AskBio was granted Pioneering Regenerative Medical Product designation (SAKIGAKE) in Japan for ametefgene parvec, and in February 2025 the company was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.1,2 Prior to that, AskBio received FDA Fast Track designation and the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency (UK MHRA) innovative medicine designation.3 All designations were for PD.<\/p>\n
AskBio is also exploring ametefgene parvec in participants in the United States with the parkinsonian subtype of MSA-P in a fully enrolled Phase I clinical trial to assess the preliminary safety, tolerability, and efficacy for this rapidly progressing neurodegenerative condition.4<\/p>\n
Ametefgene parvec is an investigational gene therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been established or fully evaluated.<\/p>\n
About Parkinson\u2019s disease\u00a0
Parkinson\u2019s disease (PD) is a progressive neurodegenerative disease.5\u00a0It has a significant impact on a person\u2019s daily life.5\u00a0In PD, the progressive death of dopamine producing nerve cells in the brain leads to the continuous loss of motor function.6 Symptoms include tremors, muscle rigidity, and slowness of movement.7\u00a0Additionally, people with PD experience non-motor symptoms, including fatigue and lack of energy, cognitive issues, and depression.7 Symptoms typically intensify over time and make everyday tasks increasingly demanding.7 The prevalence of PD has doubled over the past 25 years.5 Today, more than 10 million people worldwide are estimated to be living with PD.8 This makes it the world\u2019s second most prevalent neurodegenerative disease.9 It is also the most frequent movement disorder.5,10 At present there is no cure, and current treatment options lack the holistic management of symptoms, so there is an urgent need for new therapies.11<\/p>\n
About Parkinsonian subtype of multiple system atrophy
The parkinsonian subtype of multiple system atrophy (MSA-P) can initially be difficult to distinguish from Parkinson\u2019s disease and is marked by slow movement, lack of coordination, imbalance, dizziness, and fainting, among other symptoms.12 Individuals experience increasing difficulty with movement and autonomic dysfunction as a result of progressive loss of nerve cells in the brain and spinal cord.12 Affecting approximately 400,000 people worldwide, MSA-P is a rare disease, and its exact cause is unknown.12,13,14 Symptoms usually start to develop around the age of 50, followed by rapid progression within 5\u201310 years.12 At present there is no cure and no approved treatments for MSA-P, so there is an urgent need for new therapies.12<\/p>\n
About REGENERATE-PD About ametefgene parvec (AB-1005) About AskBio About Viralgen About Bayer References<\/p>\n 1.\u00a0\u00a0\u00a0\u00a0 Askbio.com. AskBio\u2019s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan. Available at: https:\/\/www.askbio.com\/ab-1005-and-ab-1002-receive-designation-in-japan\/<\/a>. Accessed: April 2026.<\/p>\n 2.\u00a0\u00a0\u00a0\u00a0 Askbio.com. AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson\u2019s disease investigational gene therapy. Available at: https:\/\/www.askbio.com\/askbio-receives-fda-regenerative-medicine-advanced-therapy-designation-for-parkinsons-disease-investigational-gene-therapy\/<\/a>. Accessed: April 2026.<\/p>\n 3.\u00a0\u00a0\u00a0\u00a0 Askbio.com. AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson\u2019s disease. Available at: https:\/\/www.askbio.com\/askbio-receives-fda-fast-track-and-mhra-innovation-passport-designations-for-ab-1005-investigational-gdnf-gene-therapy-for-parkinsons-disease\/<\/a>. Accessed: April 2026.<\/p>\n 4.\u00a0\u00a0\u00a0\u00a0 ClinicalTrials.gov. GDNF Gene Therapy for Multiple System Atrophy. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04680065<\/a>. Accessed: April 2026.<\/p>\n 5.\u00a0\u00a0\u00a0\u00a0 World Health Organization. Parkinson Disease. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease<\/a>. Accessed April 2026.<\/p>\n 6.\u00a0\u00a0\u00a0\u00a0 Ramesh S & Arachchige A. Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: A review of the literature. AIMS Neurosci. 2023 Aug 14;10(3):200-231.<\/p>\n 7.\u00a0\u00a0\u00a0\u00a0 National Institutes of Health. Parkinson\u2019s Disease. Available at: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/parkinsons-disease<\/a>. Accessed: April 2026.<\/p>\n 8.\u00a0\u00a0\u00a0\u00a0 Maserejian N, et al. Estimation of the 2020 Global Population of Parkinson\u2019s Disease (PD). MDS Virtual Congress 2020. Abstract number 198. Available at: https:\/\/www.mdsabstracts.org\/abstract\/estimation-of-the-2020-global-population-of-parkinsons-disease-pd<\/a>. Accessed: April 2026.<\/p>\n 9.\u00a0\u00a0\u00a0\u00a0 National Institute of Environmental Health Sciences. Neurodegenerative Diseases. Available at: https:\/\/www.niehs.nih.gov\/research\/supported\/health\/neurodegenerative<\/a>. Accessed: April 2026.<\/p>\n 10.\u00a0 Stoker T & Barker R. Recent developments in the treatment of Parkinson\u2019s Disease. F1000Res. 2020 Jul 31;9:F1000 Faculty Rev-862.<\/p>\n 11.\u00a0 Mayo Clinic. Parkinson\u2019s disease. Available at: https:\/\/www.mayoclinic.org\/diseases-conditions\/parkinsons-disease\/diagnosis-treatment\/drc-20376062<\/a>. Accessed: April 2026.<\/p>\n 12.\u00a0 NIH \u2013 Multiple System Atrophy. Available at: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/multiple-system-atrophy#toc-how-is-multiple-system-atrophy-diagnosed-and-treated. Accessed April 2026.<\/p>\n 13.\u00a0 Vanacore N, Bonifati V, Fabbrini G, et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci. 2001;22(1):97-99.<\/p>\n 14.\u00a0 Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997;49(5):1284-1288.<\/p>\n 15.\u00a0 ClinicalTrials.gov. A Study of AAV2-GDNF in Adults With Moderate Parkinson’s Disease (REGENERATE-PD). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06285643<\/a>. Accessed: April 2026<\/p>\n 16.\u00a0 Heiss J, et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease. Mov Disord. 2019 Jul;34(7):1073-1078.<\/p>\n 17.\u00a0 Kells A, et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci. 2010 Jul 14;30(28):9567-77.<\/p>\n 18.\u00a0 Lin L, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260(5111):1130-1132.<\/p>\n 19.\u00a0 Barker RA, et al. GDNF and Parkinson\u2019s Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020;10(3):875-891.<\/p>\n Forward-Looking Statements Bayer AG is a holding company with operating subsidiaries worldwide. References to \u201cBayer\u201d or \u201cthe company\u201d herein may refer to one or more subsidiaries as context requires.<\/p>\n Forward-Looking Statements AskBio ‘;<\/p>\n","protected":false},"excerpt":{"rendered":"Berlin, Germany, and Durham, N.C., USA, April 20, 2026\u00a0\u2013\u00a0AskBio Inc. (AskBio), a gene therapy company wholly owned and…\n","protected":false},"author":2,"featured_media":21193,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21161],"tags":[21182,23819,22283,21582,21583,17986,21586,21580],"class_list":["post-21192","post","type-post","status-publish","format-standard","has-post-thumbnail","category-bayer","tag-bayer","tag-cell-gene-theraphy","tag-doccheck-uk","tag-export-latestnews","tag-export-ph","tag-pharmaceuticals","tag-research-innovation","tag-specialized-press"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/21192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/comments?post=21192"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/21192\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media\/21193"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media?parent=21192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/categories?post=21192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/tags?post=21192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
REGENERATE-PD is a Phase II, randomized, double-blind, surgery controlled trial of the efficacy and safety of intraputaminal ametefgene parvec (AB-1005) in the treatment of adults (45\u201375 years) with moderate-stage Parkinson\u2019s disease.15 The trial will include an estimated number of 127 participants with trial sites located in Germany, Poland, the United Kingdom, and the United States.15 For more information about the REGENERATE-PD clinical trial, visit clinicaltrials.gov (NCT06285643<\/a>),\u00a0or visit askbio.com.<\/p>\n
Ametefgene parvec (AB-1005) is an investigational gene therapy intended to slow disease progression and improve motor outcomes in people with Parkinson\u2019s disease (PD). Composed of an adeno-associated viral vector containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, ametefgene parvec allows for stable and continuous expression of GDNF in localized regions of the brain after direct neurosurgical injection with convection-enhanced delivery.16,17 In nonclinical studies, GDNF has been shown to promote the survival and morphological differentiation of dopaminergic neurons, which could aid in the preservation and restoration of dopaminergic neuronal circuitries normally lost in the disease.17,18 GDNF has long been evaluated as a potential disease-modifying treatment for diseases, such as PD which are marked by progressive degeneration of midbrain dopaminergic neurons.18 Through a combination of an investigational gene therapy and innovative neurosurgical delivery approach, building on the promising outcomes of the open-label Phase 1b trial, we can now test the GDNF hypothesis by getting this neurotrophic factor to these degenerating nigrostriatal neurons in a well-controlled clinical study to understand the effects of GDNF in a moderate PD population.19<\/p>\n
AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to steering gene therapy into a new era where it can transform the lives of a wider range of people living with rare and more common diseases. The company maintains a portfolio of clinical programs across a range of disease indications related to a single gene or multiple factors across cardiovascular, central nervous system, and neuromuscular conditions, with a clinical-stage pipeline that includes investigational therapeutics for congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson\u2019s disease, and Pompe disease. AskBio\u2019s end-to-end gene therapy platform includes our Pro10\u2122 technology and Aava\u2122 manufacturing platform, which make gene therapies more accessible by making research and commercial grade manufacturing more affordable. With global headquarters in Research Triangle Park, North Carolina, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing. An early innovator in the gene therapy field with over 900 employees in five countries, the company holds more than 600 patents and patent applications in areas such as AAV production and chimeric capsids. Learn more at\u00a0http:\/\/www.askbio.com<\/a> or follow us on\u00a0LinkedIn<\/a>.<\/p>\n
Viralgen is a leading contract development and manufacturing organization (CDMO) specializing exclusively in adeno-associated virus (AAV)\u2013based gene therapies. Founded in 2017 as a subsidiary of AskBio Inc. within the Bayer AG group, Viralgen provides end-to-end support from early development through large-scale commercial production. Leveraging its proprietary Pro10\u2122 suspension cell line and Aava\u2122 manufacturing platform, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes. Located in San Sebasti\u00e1n, Spain, its state-of-the-art facility includes three cGMP suites with 2,000-liter capacity each, certified by the AEMPS\/EMA, and integrates services such as plasmid production, process optimization, fill-finish, and in-house QC testing. With more than 1,200 AAV batches produced, Viralgen delivers reliable, efficient solutions that help bring life-changing gene therapies to patients with greater speed and consistency. For more information, visit https:\/\/viralgen.com\/<\/a>.<\/p>\n
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, \u201cHealth for all, Hunger for none,\u201d the company\u2019s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000\u00a0people and had sales of 45.6\u00a0billion euros. R&D expenses amounted to 5.8\u00a0billion euros. For more information, go to www.bayer.com<\/a>.<\/p>\n
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer\u2019s public reports which are available on the Bayer website at www.bayer.com<\/a>. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.<\/p>\n
This press release contains \u201cforward-looking statements.\u201d Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cwill,\u201d \u201cintends,\u201d \u201cpotential,\u201d \u201cpossible,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding AskBio\u2019s clinical trials. These forward-looking statements involve risks and uncertainties, many of which are beyond AskBio\u2019s control. Known risks include, among others: AskBio may not be able to execute on its business plans and goals, including meeting its expected or planned clinical and regulatory milestones and timelines, its reliance on third-parties, clinical development plans, manufacturing processes and plans, and bringing its product candidates to market, due to a variety of reasons, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our third-party collaborators and partners, and regulatory, court or agency feedback or decisions, such as feedback and decisions from the United States Food and Drug Administration or the United States Patent and Trademark Office. Any of the foregoing risks could materially and adversely affect AskBio\u2019s business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. AskBio does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.<\/p>\n